Genmab — Marts 2017
-
Via
-
-
-
Roche: Soars on positive results from Aphinity study - Reuters News
02-Mar-2017 09:02:56
** Roche ROG.S shares jump 6.5 pct to 9 mth high after positive reults from key Aphinity study
** Finds that its Perjeta and Herceptin drugs with chemotherapy reduce recurrence of aggressive breast cancer or death compared to Herceptin and chemo
** "These positive results remove a major overhang for Roche (we and consensus were expecting up to 10% negative reaction in case of failure)," Morgan Stanley says -
Der blev stor-solgt i går fra Danske bank (warrants). Før det var det AB der pressede kursen voldsomt. Vi har ikke nogen nyheder rundt hjørnet som vi kender til. Vi har forholdsvis store stigninger bag os og alligevel stiger vi i dag over 1% pt med AB på den rigtige side af stregen
-
På vej mod 1.400
-
-
Sådanne stille dage har vi en sjælden gang i mellem.
-
Ofatumumab article in The Lancet http://thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30019-4/fulltext
-
with respect to this study (idelalisib in combination with ofatumumab)
: https://www.clinicaltrials.gov/ct2/show/NCT01659021?term=NCT01659021&rank=1 -
This article/ literature study claims "The combination of daratumumab, lenalidomide, and dexamethasone was identified as the best treatment option for relapsed and/or refractory multiple myeloma" http://ascopubs.org/doi/10.1200/JCO.2016.71.1663
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind